Inhibition of phosphodiesterase 10A increases the responsiveness of striatal projection neurons to cortical stimulation

Journal of Pharmacology and Experimental Therapeutics

Volumn 328, Issue 3, 2009, Pages 785-795

  Threlfell, Sarah ^a   Sammut, Stephen ^a   Menniti, Frank S ^b   Schmidt, Christopher J ^b   West, Anthony R ^a  

^a ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 [PYRIDIN 4 YL 1 (2,2,2 TRIFLUOROETHYL) 1H PYRAZOL 3 YL]PHENOXYMETHYL]QUINOLINE SUCCINIC ACID; PAPAVERINE; PHOSPHODIESTERASE; PHOSPHODIESTERASE 10A; QUINOLINE DERIVATIVE; TP 10; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIDROMIC STIMULATION; ARTICLE; BRAIN DEPTH STIMULATION; BRAIN NERVE CELL; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC TRANSMISSION; DRUG DOSE COMPARISON; ENZYME INHIBITION; MALE; MICRODIALYSIS; NONHUMAN; PRIORITY JOURNAL; RAT; WHITE MATTER;

ANIMALS; CORPUS STRIATUM; ELECTRIC STIMULATION; ELECTROPHYSIOLOGY; EVOKED POTENTIALS; FRONTAL LOBE; GLOBUS PALLIDUS; MALE; MICRODIALYSIS; NEURONS; PAPAVERINE; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PYRAMIDAL CELLS; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA;

EID: 62449195496     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.108.146332     Document Type: Article

References (41)

1. Ballion B, Mallet N, Bézard E, Lanciego JL, and Gonon FF (2008) Intratelencephalic corticostriatal neurons equally excite striatonigral and striatopallidal neurons and their discharge activity is selectively reduced in experimental parkinsonism. Eur J Neurosci 27:2313-2321.
2. Bender AT and Beavo JA (2006) Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 58:488-520.
3. Berke JD, Paletzki RF, Aronson GJ, Hyman SE, and Gerfen CR (1998) A complex program of striatal gene expression induced by dopaminergic stimulation. J Neurosci 18:5301-5310.
4. Bolam JP, Hanley JJ, Booth PA, and Bevan MD (2000) Synaptic organisation of the basal ganglia. J An at 196:527-542.
5. Calabresi P, Gubelhni P, Centonze D, Picconi B, Bernardi G, Chergui K, Svenningsson P, Fienberg AA, and Greengard P (2000) Dopamine and cAMP-regulated phosphoprotein 32 kDa controls both striatal long-term depression and long-term potentiation, opposmg forms of synaptic plasticity. J Neurosci 20:8443-8451.
6. Cepeda C, André VM, Yamazaki I, Wu N, Kleiman-Weiner M, and Levine MS (2008) Differential electrophysiological properties of dopamine Dl and D2 receptorcontaining striatal medium-sized spiny neurons. Eur J Neurosci 27:671-682.
7. Colwell CS and Levine MS (1995) Excitatory synaptic transmission in neostriatal neurons: regulation by cyclic AMP-dependent mechanisms. J Neurosci 15:1704-1713.
8. Coskran TM, Morton D, Menniti FS, Adamowicz WO, Meiman RJ, Ryan AM, Strick CA, Schmidt CJ, and Stephenson DT (2006) Immunohistochemical locahzation of phosphodiesterase 10A in multiple mammalian species. J Histochem Cytochem 54:1205-1213.
9. DeLong MR and Wichmann T (2007) Circuits and circuit disorders of the basal ganglia. Arch Neurol 64:20-24.
10. Everitt BJ and Robbins TW (2005) Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. Nat Neurosci 8:1481-1489.
11. Fujishige K, Kotera J, and Omori K (1999) Striatum- and testis-specific phosphodiesterase PDE10A isolation and characterization of a rat PDE10A. Eur J Biochem 266:1118-1127.
12. Gertler TS, Chan CS, and Surmeier DJ (2008) Dichotomous anatomical properties of adult striatal medium spiny neurons. J Neurosci 28:10814-10824.
13. Graybiel AM (2000) The basal ganglia. Curr Biol 10:R5Q9-R511.
14. Greengard P (2001) The neurobiology of slow synaptic transmission. Science 294:1024-1030.
15. Groenewegen HJ, van den Heuvel OA, Cath DC, Voorn P, and Veltman DJ (2003) Does an imbalance between the dorsal and ventral striatopalhdal systems play a role in Tourette's syndrome? A neuronal circuit approach. Brain Dev 25:S3-S14.
16. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals, 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington, DC.
17. Kapur S (2004) How antipsychotics become anti-"psychotic": from dopamine to salience to psychosis. Trends Pharmacol Sci 25:402-406.
18. Kotera J, Sasaki T, Kobayashi T, Fujishige K, Yamashita Y, and Omori K (2004) Subcellular localization of cyclic nucleotide phosphodiesterase type 10A variants, and alteration of the localization by cAMP-dependent protein kin a se-de pendent phosphorylation. J Biol Chem 279:4366-4375.
19. Kreitzer AC and Malenka RC (2007) Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models. Nature 445:643-647.
20. Lei W, Jiao Y, Del Mar N, and Reiner A (2004) Evidence for differential cortical input to direct pathway versus indirect pathway striatal projection neurons in rats. J Neurosci 24:8289-8299.
21. Loughney K, Snyder PB, Uher L, Rosman GJ, Ferguson K, and Florio VA (1999) Isolation and characterization of PDE10A, a novel human 3', 5'-cyclic nucleotide phosphodiesterase. Gene 234:109-117.
22. Lugnier C (2006) Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther 109:366-398.
23. Mallet N, Le Mome C, Charpier S, and Gonon F (2005) Feedforward inhibition of projection neurons by fast-spiking GABA interneurons in the rat striatum in vivo. J Neurosci 25:3857-3869.
24. Menniti FS, Chappie TA, Humphrey JM, and Schmidt CJ (2007) Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia. Curr Opin Investig Drugs 8:54-59.
25. Menniti FS, Faraci WS, and Schmidt CJ (2006) Phosphodiesterases in the CNS:targets for drug development. Nat Rev Drug Discov 5:660-670.
26. Nishi A, Kuroiwa M, Miller DB, O'Callaghan JP, Bateup HS, Shuto T, Sotogaku N, Fukuda T, Heintz N, Greengard P, et al. (2008) Distinct roles of PDE4 and PDE10A in the regulation of cAMP/PKA signaling in the striatum. J Neurosci 28:10460-10471.
27. Ondracek JM, Dec A, Hoque KE, Lim SA, Rasouli G, Indorkar RP, Linardakis J, Klika B, Mukherji SJ, Burnazi M, et al. (2008) Feed-forward excitation of striatal neuron activity by frontal cortical activation of nitric oxide signaling in vivo. Eur J Neurosci 27:1739-1754.
28. Paxinos G and Watson C (1986) The Rat Brain in Stereotaxic Coordinates, Academic Press, New York.
29. Sammut S, Park DJ, and West AR (2007) Frontal cortical afferents facilitate striatal nitric oxide transmission in vivo via a NMDA receptor and neuronal NOS-dependent mechanism. J Neurochem 103:1145-1156.
30. Sano H, Nagai Y, Miyakawa T, Shigemoto R, and Yokoi M (2008) Increased social interaction in mice deficient of the striatal medium spiny neuron-specific phosphodiesterase 10A2. J Neurochem 105:546-556.
31. Schmidt CJ, Chapm DS, Cianfrogna J, Gorman ML, Hajos M, Harms JF, Hoffman WE, Lebel LA, McCarthy SA, Nelson FR, et al. (2008) Preclinical characterization of selective PDE10A inhibitors: A new therapeutic approach to the treatment of schizophrenia. J Pharmacol Exp Ther 325:681-690.
32. Seeger TF, Bartlett B, Coskran TM, Culp JS, James LC, Krull DL, Lanfear J, Ryan AM, Schmidt CJ, Strick CA, et al. (2003) Immunohistochemical localization of PDE10A in the rat brain. Brain Res 985:113-126.
33. Siuciak JA, Chapin DS, Harms JF, Lebel LA, McCarthy SA, Chambers L, Shrikhande A, Wong S, Menniti FS, and Schmidt CJ (2006a) Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis. Neuropharmacology 51:386-396.
34. Siuciak JA, McCarthy SA, Chapin DS, Fujiwara RA, James LC, Williams RD, Stock JL, McNeish JD, Strick CA, Menniti FS, et al. (2006b) Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: evidence for altered striatal function. Neuropharmacology 51:374-385.
35. Soderling SH, Bayuga SJ, and Beavo JA (1999) Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A. Proc Natl Acad Sci USA 96:7071-7076.
36. Surmeier DJ, Ding J, Day M, Wang Z, and Shen W (2007) Dl and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons. Trends Neurosci 30:228-235.
37. A receptor-mediated inhibition of rat substantia nigra dopaminergic neurons by pars reticulata projection neurons. J Neurosci 15:3092-3103.
38. West AR and Grace AA (2004) The nitric oxide-guanylyl cyclase signaling pathway modulates membrane activity States and electrophysiological properties of striatal medium spiny neurons recorded in vivo. J Neurosci 24:1924-1935.
39. Wilson CJ (2004) Basal Ganglia, Oxford University Press, Oxford, UK.
40. Winterer G and Weinberger DR (2004) Genes, dopamine and cortical signal-to-noise ratio in schizophrenia. Trends Neurosci 27:683-690.
41. Xie Z, Adamowicz WO, Eldred WD, Jakowski AB, Kleiman RJ, Morton DG, Stephenson DT, Strick CA, Williams RD, and Menniti FS (2006) Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase. Neuroscience 139:597-607.